Even though MCL1 amplifications are low in CRC cell lines compared to other human tumor cell lines, MCL1 can still limit the activity of Bcl-xL inhibitors and other chemotherapeutic agents in CRC [17–19] and additional solid tumor indications [15, 20]. This evidence concerns the gene BCL2L1 and colorectal carcinoma.